SG Americas Securities LLC Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

SG Americas Securities LLC bought a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,869 shares of the biotechnology company’s stock, valued at approximately $53,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. KBC Group NV increased its position in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the period. Wolverine Trading LLC acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at about $51,000. Legacy Capital Group California Inc. acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at about $59,000. Virtu Financial LLC acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at about $78,000. Finally, Quantinno Capital Management LP increased its position in Ironwood Pharmaceuticals by 40.0% in the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 5,482 shares during the period.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. This represents a 3.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 208,742 shares of company stock worth $405,343. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Trading Up 3.6 %

NASDAQ IRWD opened at $2.01 on Friday. The business’s 50 day moving average is $3.60 and its two-hundred day moving average is $4.17. Ironwood Pharmaceuticals, Inc. has a 12-month low of $1.59 and a 12-month high of $15.70. The stock has a market capitalization of $321.66 million, a price-to-earnings ratio of -67.00 and a beta of 0.29.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IRWD. Craig Hallum dropped their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, JMP Securities dropped their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $10.67.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.